News & Trends - Pharmaceuticals

Sanofi’s second brand of insulin glargine on the PBS

Health Industry Hub | July 29, 2020 |
[Total: 1    Average: 4/5]

Pharma News: Sanofi’s Lantus (Insulin glargine U100) is a vital treatment for patients with type 1 and type 2 diabetes.

Changes have been made from 1 July 2020 to the PBS listings for insulin glargine, as the brands Lantus and Lantus SoloStar are no longer available on the PBS.

Lantus was delisted due to biosimilar insulins arriving in Australia. Alphapharm’s Semglee was listed on the PBS in October 2019. It is not the first biosimilar insulin glargine on the Australian market. Back in 2015, Abasria was approved by the TGA which marketed by Eli Lilly and available as a private script only.

Sanofi’s OPTISULIN is the same formulation as Lantus and is available in the same familiar presentations and devices, including the SoloStar pre-filled device and cartridges for use in either AllStar Pro and JuniorStar reusable pens. It requires no dose adjustment when transitioning from Lantus and patients transitioning to OPTISULIN should continue to administer their dose at the same time of the day and monitor their blood glucose levels as directed by their treating clinician.

There is also the option for clinicians to move patient to a second generation basal insulin. Sanofi’s Toujeo (insulin glargine U300 or GLA-300) may be a an alternate option to consider with a simple initiation regimen and a reduced risk of hypoglycaemia.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

Marketing Pharma Biotech Healthcare - PRIME Awards 2020 finalists announced

PRIME Awards 2020 finalists announced

Health Industry Hub | August 7, 2020 |

The finalists for PRIME Awards 2020 have been named, with winners to be announced via a virtual ceremony on Thursday […]

More


News & Trends - Pharmaceuticals

Pharma News - New Ventolin inhalers with dose counter reimbursed on the PBS

New Ventolin inhalers with dose counter reimbursed on the PBS

Health Industry Hub | August 7, 2020 |

Pharma News: GSK Australia is pleased to announce that a dose counter has been added to VENTOLIN (salbutamol sulfate) metered […]

More


News & Trends - Medical Technology

MedTech News - Siemens Healthineers to acquire Varian in $16.4bn deal

Siemens Healthineers to acquire Varian in $16.4bn deal

Health Industry Hub | August 5, 2020 |

MedTech News: Siemens Healthineers shall acquire Varian Medical Systems for approximately USD$16.4 billion. Since 2012, Siemens Healthineers and Varian have […]

More


News & Trends - Pharmaceuticals

Pharma News - New anti-cancer drug for prostate cancer

New anti-cancer drug for prostate cancer

Health Industry Hub | August 5, 2020 |

Pharma News: A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis […]

More